PDA Technical Report No. 86 (TR 86) Industry Challenges and Current Technologies for Pharmaceutical Package Integrity Testing (single user digital version)

Published
May 2021
ISBN
9781945584275
Pages
57
PDA Item Number
43553

Premium Members: to claim your annual free technical document download, email membership@pda.org and indicate the document you wish to claim.

Format
PDF Single user
Member Price
$180.00
Nonmember Price
$325.00
Government Price
$180.00

This technical report is a consensus-based resource surrounding the challenges encountered in using complex package systems and introduces important elements to consider in decision-making. It also offers an examination of the technologies available for package integrity testing not yet established by peer-reviewed research. This technical report focuses on the challenges facing the pharmaceutical industry that use complex packaging systems for sterile drugs and biologics (e.g., syringes, syringe assemblies, bulk containers). It also presents information on some innovative methods for package integrity testing using existing technologies, including the potential impact of cryogenic conditions. The intent is to update information and incorporate experiential learning which is not addressed in PDA Technical Report 27 and USP<1207>. It also serves as a technical resource, focusing particularly on sterile products and encouraging a risk-based approach and leveraging testing to better understand, analyze, and eliminate the risks during developmental phases. Use of the appropriate testing during each manufacturing phase can help in evaluating and mitigating residual risks.

Available to download. Prior to purchase please view the download instructions and Terms of Usage.
Format: PDF (1 file 2.22 MB)

*To purchase licensing, please contact PDA at info@pda.org.

Table of Contents

Table of Contents:

Click here to download >>> Detailed Table of Contents
  1. Introduction
  2. Glossary
  3. Challenges with Methodologies
  4. Challenges with Package Design
  5. Innovative Methods for Existing Technologies
  6. Additional Considerations for Package Integrity Profiling
  7. Conclusion
  8. References
  9. Additional Reading

Figures and Tables Index

About the Authors

Tia Bush, Amgen (chair)

John Ayres, MD, Pharma Safety Solutions

Cecile Begat, Bayer

Antonio Burazer, Takeda

Fran DeGrazio, West Pharmaceutical Services

Carol Flynn, MEng, Corning

Abizer Harianawala, Stevanato Group

Paul Kinsey, GSK

Jahanvi Miller, MBA, PDA

Anthony Perry, Schott

John Shabushnig, Ph.D., Insight Pharma Consulting

Xu Song, MEng, Astra Zeneca

Hervé Soukiassian, MEng, BD

Andrew Spasoff, MS, Astra Zeneca

Amy Stanton, Amgen

Dorothee Streich, Ph.D., Bayer

Rick Watson, Merck

Elastomer Sub-team

Ravi Patel, West Pharmaceutical Services (Co- Chair)

John Rech, West Pharmaceutical Services (Co- Chair)

Andrea DeSalvia, Aptar

Wadi Farach, MEng, Amgen

Gert Gregoire, MBA, Datwyler

Lucia Ino, West Pharmaceutical Services

Denise Schnaufer, Merck

Larry Staub, MS, Quality Advisor

Julie Suman, Next Breath

Wadi Farach, MEng, Amgen

Rick Watson, Merck

Glass Sub-Team

Hervé Soukiassian, MEng, BD (Co-Chair)

Paul Kinsey, GSK (Co-Chair)

Alfred Breunig, Nipro Pharma Packaging

Benjamin Coutan, MBA, Gerresheimer

Wadi Farach, MEng, Amgen

Carol Flynn, MEng, Corning Incorporated

Martina Marchioro, Stevanato Group

Didier Morel, BD

Anthony Perry, Schott

Volker Rupertus, Schott AG

Daniele Zuccato, Schott AG